Reservoir offers the chance to preserve today’

Diagnostic Imaging Centers of Texas will pair MR

A Lancet Neurology study of 130 blood proteins i

Mighty Therapeutics and the University of Washin

Lovehoney’s hormone-free MenoPulse device laun

Rapalogix Health announced the publication of a p

Sironax said on 13 October that it has reached ab

The Rhode Island Life Science Hub and Cognito The

Rona Therapeutics granted Roche an exclusive worl

Forecast for rapid growth by 2033, with disease-

Arvinas presented early biomarker data on ARV-10

Better U and Evernow have joined forces to pair

QIMA Life Sciences launches SQINGEVITY, bringing

Small open-label study of ATR-258 saw fat loss,

IBio’s eight-week obese nonhuman primate study

The United States Patent and Trademark Office has

United Therapeutics will present two oral and fiv

Boehringer Ingelheim widens its kidney-disease p

A two-year partnership with Ultrahuman aims to c

GPX4-targeting therapy reduces epigenetic age ma

Rubedo Life Sciences released Phase 1b clinical f

Function and Google Health announced a partnershi

Immorta Bio completed planned preclinical studies

Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well beyond glucose. There is a neat irony in a fingerstick company funding the device that might make fingersticks unnecessary. Ascensia Diabetes Care, maker of the CONTOUR blood glucose meters, has led a $36 million Series B in Sava Technologies, the London healthtech whose microsensor reads glucose from just beneath the skin. It has also agreed to commercialize and distribute the device in Europe once it is approved – which suggests Ascensia sees more future in the sensor than in defending the meter. Sava has now raised $68 million in total, and this round goes on the less photogenic end of medtech: production lines, commercial readiness and a pivotal clinical study. CE approval and a European launch are penciled in for 18 to 24 months from now. Glucose is the first molecule on Sava’s list. It was never meant to be the last. Longevity.Technology: Sava’s latest funding round is significant, but arguably more interesting is its partnership with Ascensia – a sign that the company is moving beyond proving its tech works to tackling the rather less glamorous, but equally important,…

MUST’s RETRO-EPIGERNA team won $1 million and

A new partnership is combining a blood test, a c

Neither the FDA nor EMA recognizes aging as an i

Oxford biotech secures $47 million to scale cell

The MINIGRAPH consortium, funded by the European

Avaí Bio and Austrianova held a first joint stee

Restore Hyper Wellness and Niagen Bioscience have

Life Biosciences released interim Phase 1 data fr

Deep Longevity’s new US telehealth platform, A

The Parkinson’s enzyme therapy is still headin

The Austin-based microbiome testing company raise

Swedish biotech will present the Phase II ADVANC

Cognition Therapeutics will meet the agency on 2

European Parliament conference calls for coordin

Jupiter Neurosciences has dosed the first patient

Cerevance announced positive topline results from

AgelessRx has launched GHK-Cu Cream, a prescripti

First-in-human ER-100 data support dose escalati

HepaRegeniX’s darizmetinib clears milestone in

Novartis’ President of Biomedical Research, Fi

Promis Neurosciences appointed Ivana Rubino, Ph.

Shift published research in Nature Biotechnology

Maze Therapeutics will present data for its lead

A peer-reviewed preclinical study published in Ex

Bexorg was awarded up to $28.

Researchers say women in Bolotana are reaching 1